Kornimate/medical-research-clean huggingface dataset:
impact of chemotherapy and regenerative markers of liver regeneration after liver resection for liver metastases

Conditions: Liver Regeneration; Liver Metastases

Summary: liver is special organ, which can regenerate. on that ability there are many treatment modalities, where liver resection is performed, especially in cancer patients with liver metastases. liver regeneration provides an opportunity for these patients to undergo multiple treatment regimes and liver resections to achieve curability. there are many factors that impair liver regeneration. one of these factors is chemotherapy. literature data on impact of chemotherapy to liver regeneration is ambiguous. therefore we aim to research impact of chemotherapy to liver regeneration.

liver is the largest parenchymal organ responsible for over 500 different functions in human body, which are detoxification of various toxins, drugs, synthesis of proteins and enzymes, coagulation factors. liver is special organ, which can regenerate. if 75% of liver is removed it can regenerate to its normal size. liver volume is very important to liver function, if there is volume insufficiency it could lead to liver failure in addition to other factors that impair liver regeneration. on that regenerative ability there are many treatment modalities, when liver resection is performed, especially in cancer patients with liver metastases. modern treatment modalities are based on combination of different treatments, surgical and chemotherapeutic. on the other hand, side effects of chemotherapy should not be discarded, which can increase patient morbidity and mortality. thus, liver regeneration provides an opportunity for these patients to undergo multiple treatment regimes and liver resections to achieve curability. literature data on impact of chemotherapy to liver regeneration is ambiguous. therefore we aim to research impact of chemotherapy to liver regeneration.

Eligibility criteria:
inclusion criteria: • patients with liver lesions, who are eligible for liver resection exclusion criteria: * pregnant women * liver resection is not performed

Keywords: liver metastases liver regeneration markers
comparative study between steroid plus anesthetic block and crf in participants with hip osteoarthritis

Conditions: Hip Osteoarthritis; Chronic Pain

Summary: this will be a prospective, multi-center, double-blinded, randomized study designed to compare the efficacy of conventional radiofrequency (crf) and the anesthetic block of the anterior sensory branches to the hip to control pain and improve function related to hip osteoarthritis.

this prospective, double-blinded (participant and outcome assessor) clinical trial was designed to investigate the results of the intervention continuous radiofrequency (crf) in the treatment of participants with chronic hip pain secondary to hip osteoarthritis. participants will be randomized in a 2-arm, parallel groups. the intervention group will be submitted to an anesthetic block of the sensory branches of femoral and obturator nerves to the hip, with 1 ml of 1% lidocaine with 1ml of steroid (betamethasone dipropionate 5 mg/ml + betamethasone sodium phosphate 2 mg/ml) for each branch, followed by denervation with crf (22¬gauge 5¬mm active tip cannula, 10cm in length) with the tip temperature set at 90° c in a single cycle of 90 min. the sham group will be submitted to the same anesthetic block, followed by a simulation of crf use. the surgeon performing the procedures will only be informed of the randomization after completing the anesthetic block on the participants to avoid bias at its accuracy. participants will be evaluated at four follow-up: before intervention and after 1, 12, and 24 weeks, to access the western ontario and mcmaster universities score (womac) as the primary outcome.

Eligibility criteria:
inclusion criteria: * participants 18 years or older * symptomatic unilateral hip osteoarthritis (oa) * pain for more than 6 months in the groin, anterior, anterolateral ou lateral region * oa radiologically classified as kellgren and lawrence tipo ii-iv, * vas ≥ 4 * considered non-responder to conservative treatment for the participant for 6 months. * in case of difficulty in selecting participants with symptomatic unilateral oa, symptomatic bilateral hip oa will be admitted and submitted to the same treatment on both sides, after notification and approval from the ethic board of each institution involved. exclusion criteria: * participants with radiculopathy ipsolateral * knee oa ipsolateral, * previous hip arthroplasty * pain exclusively in the posterior region of the hip * infiltration of the hip for less than 3 months * neurological disease compromising gait * peripheral neuropathy * psychiatric disease that compromise collaboration with the protocol * implanted pacemaker * prothrombin activity time (pt/inr) \> 3 and * litigation process related to the disease.
the effect of different doses of remifentanil on kidney function during robot assisted prostatectomy - a retrospective study

Conditions: Prostate Cancer

Summary: robot assisted prostatectomy reduces the patients' postoperative pain and leads to rapid rehabilitation. but pneumoperitoneum affects the kidney. the increase of stress hormone reduces the glomerular filtration and the vaso-contraction of renal vessels leads the renal ischemia. remifentanil is analgesics coupled with μ opioid receptor. in high dose of remifentanil, it is associated with κ and δ receptors, which leads to renal protection effect in animal study. also, remifentanil infusion during anesthesia showed a diuretic effect. the purpose of this study is to investigate the remifentanil effect on renal function during robot assisted prostatectomy.


Eligibility criteria:
inclusion criteria: * ages \> 19 years and \< 85 years * the patients undergoing a general anesthesia for robot assisted prostatectomy exclusion criteria: * incomplete record * history of opioid or steroid using * solitary kidney * history of kidney transplantation
stress reduction intervention for enhancing treatment outcome for depressed minority patients

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to determine the usefulness of a stress reduction treatment in helping minority patients with major depression get better. subjects will receive six weeks of either mindfulness-based stress reduction and problem solving therapy or psychoeducation.

the purpose of this study is to determine the usefulness of a stress reduction treatment compared to psychoeducation in helping minority patients with major depression get better. the study will last 10 weeks. during the main portion of the study, subjects will receive either individual weekly sessions of stress-reduction therapy or psychoeducation for six weeks. the stress reduction therapy will consist of mindfulness-based stress reduction and problem solving therapy, which focuses on linking psychological problems with psychosocial issues and helping you use your skills and resources to improve your functioning. the psychoeducation will consist of six sessions of education on depression and the treatment and management of symptoms. each session will last 50 minutes, and four of the visits will also include filling out questionnaires which will take approximately 15-30 minutes to complete. one month after the last session, subjects will come in for a follow-up visit with a study clinician to see how they are doing and to fill out questionnaires.

Eligibility criteria:
inclusion criteria: * meet criteria for current major depressive disorder * men or women aged 18-75 who self-identify as a member of a racial or ethnic minority group * has a pcp, therapist, psychiatrist, etc aware of their depression. or, subject agrees to seek outside mental health treatment/management exclusion criteria: * pregnancy

Keywords: depression major depression
clinical specialty queue for gestational trophoblastic neoplasia

Conditions: Gestational Trophoblastic Neoplasia

Summary: the aim of this study is to establish a bidirectional cohort study of gtn specific diseases, including 1020 retrospective cases queue and 1000 prospective cohorts. based on the clinical collaboration system for gynecological tumors in multiple tertiary hospitals across the country, establish unified criteria for case inclusion and exclusion, and establish a multi center clinical queue for gtn; collect baseline information of gtn patients, such as age, reproductive history, environmental and social information, genetic related information, physical examination, physicochemical, imaging, and pathological information; collect biological specimens such as blood/tissue from patients; collect information related to the diagnosis, treatment plan, human chorionic gonadotropin (hcg) levels, and toxic side effects of patients during the diagnosis and treatment period; after the end of treatment, follow-up blood hcg levels, imaging, fertility status, as well as recurrence and metastasis status, are conducted to track prognosis, thus building a clinical diagnosis and treatment information database, forming a standardized follow-up system for gtn, identifying high-risk factors for gtn chemotherapy resistance, constructing a precise evaluation model for gtn resistance, and providing high-level evidence-based medicine for effectively improving the initial treatment efficacy of gtn.


Eligibility criteria:
inclusion criteria: * ① age ≥ 18 years old; ② patients clinically diagnosed with gtn (including invasive cases) molar pregnancy, choriocarcinoma, pstt, ett); ③ complete informed consent for enrollment. exclusion criteria: * ① having mental illness or cognitive impairment, unable to cooperate in completing the investigation with patients with concurrent malignant tumors; ③ participants with severe missing follow-up data.
development of reward processing in prenatally exposed adolescents and young adults

Conditions: Pre-natal Cocaine Exposure; Risk-Taking

Summary: reward processing will be examined in prenatally exposed emerging adults in a longitudinal design. participants will be followed for one year to see if neural markers of reward processing prospectively predict risk-taking behavior.

this cohort will be drawn from a pre-existing cohort of individuals recruited as part of an already existing study, and who have been followed since birth. reward processing will be measured in two temporally close testing sessions involving two methodologies, electrophysiology and fmri. information will also be collected pertaining to experimental and problematic drug use, as well as information about mood, at the recording sessions. drug use and mood information will then be collected once again in quarterly follow-up sessions for one year. the goal is to examine if pce status and reward processing are risk factors for problematic drug abuse and risky behaviors in emerging adulthood, and if these factors interact to increase such risk.

Eligibility criteria:
inclusion criteria: 1. ability to provide written informed consent and to comply with all study procedures. 2. healthy emerging adults between 18-20 years of age (the age of the currently followed sample at the time of the proposed start date). exclusion criteria: * 1. a serious neurological or endocrine disorder or any medical condition or treatment known to affect the brain. 2. a medical condition that requires treatment with a medication with psychotropic effects. 3. evidence of stroke or space occupying lesions observed on conventional, clinical mr images. 4. any contraindications to mri scanning (i.e., metal implants, pacemakers, etc.) 5. history of loss of consciousness (loc) for longer than 30 minutes or loc with any neurological sequelae. 6. dsm-5 criteria for intellectual disability. 7. current or a history of active neurological or psychiatric disorders, such as psychosis, bipolar illness, major depression, organic brain disease, dementia or dsm-v axis i psychiatric disorder, including current alcohol or substance disorders. participants will not be excluded for substance or alcohol use, only the presence of substance disorders. 8. current pregnancy. female participants will be excluded if they report being currently pregnant or present positive for pregnancy after being given a urine test at the time of recruitment or scanning. if they become pregnant during the one-year follow-up duration of the study after the mri scan is completed, they will remain in the study for the quarterly follow-ups and be referred to pre-natal care if they have not begun such care already.

Keywords: substance abuse
an innovative conversational agent (quitbot) for smoking cessation

Conditions: Cigarette Smoking-Related Carcinoma

Summary: this phase iii trial compares two remote digital smoking cessation programs to see how well they work for quitting smoking.

outline: participants are randomized to 1 of 2 groups. both groups receive access to a 42-day quit smoking program. group i: experimental program, for 42 days to support quitting smoking. after the completion of study, patients are followed up at 3, 6, and 12 months. group ii: control program, for 42 days to support quitting smoking. after the completion of study, patients are followed up at 3, 6, and 12 months.

Eligibility criteria:
inclusion criteria: * age 18 or older * smokes at least one cigarette a day for the past 12 months * wants to quit cigarette smoking within the next 30 days (consistent with text messaging intervention trials) * if concurrently using any other nicotine or tobacco products, wants to quit using them within the next 30 days * interested in learning skills to quit smoking * willing to be randomly assigned to either intervention * resides in united states (us) and will continue to reside in the us for the next 12 months * has at least daily access to their own smartphone * has text messaging on their smartphone and knows how to download a smartphone application * willing and able to read in english, and * not using other smoking cessation interventions (this eligibility requirement helps ensure results are due to the treatments we recommend rather than those that participants are doing on their own.) exclusion criteria: * the reverse of the inclusion criteria

Keywords: smoking smoking cessation quitting smoking chatbot
cardiovascular diseases in elderly asthma

Conditions: Asthma

Summary: this study is a cross-sectional study to evaluate the relationship between coronary calcium score and clinical parameters of asthma such as onset of disease, lung function parameter and airway inflammation parameter (sputum eosinophil or feno) in korean elderly asthma (regardless of whether they have concomittent copd or not) patients

subjects who visited allergy clinic in smg-snu boramae medical center for asthma or aco will be recruited consecutively. subjects who meets the inclusion criteria and agree to participate in the study will take coronary artery calcium scoring ct and asthma ct (inspiration and expiration images). the correlation between the degree of coronary calcification and airway diameter, airway wall thickness, air-trapping and emphysema will be evaluated as well as clinical parameters of asthma. we will also compare those correlations from the images of healthy control subjects who performed the coronary calcium scoring ct for health checkup purpose.

Eligibility criteria:
inclusion criteria: * if the doctor has been diagnosed with asthma and one or more of the following criteria is met; 1. fev1 increased more than 12% \& 200 ml after 10-20 minutes of inhalation of short-acting bronchodilator (200-400 mg salbutamol) 2. positive bronchial provocation tests (methacholine, mannitol, exercise, aspirin, etc.) 3. fev1 increased more than 12% \& 200 ml from baseline fev1 after anti-inflammatory treatment for 4 weeks or longer. exclusion criteria: * those who were already diagnosed and treated for coronary artery diseases. * those with other structural lung diseases such as tuberculosis destroyed lung and interstitial lung diseases * those who are unable to conduct a test or questionnaire due to severe systemic illness, or cognitive dysfunction. * those who are participating in other clinical trial using ind(investigational new drug) or finished other clinical trial within 30 days. * those who refuse to participate in the study or withdraw the consent.
bioflow-iii romania satellite registry

Conditions: Coronary Artery Disease; Myocardial Ischemia

Summary: this registry is a clinical post-market evaluation of the orsiro less in subjects requiring coronary revascularization with drug eluting stents (des).

for the majority of coronary artery disease (cad), treatment with percutaneous transluminal coronary angioplasty (ptca) provides high initial procedural success. however, the medium to long-term complications range from rather immediate elastic recoil or vessel contraction to longer processes like smooth muscle cell proliferation and excessive production of extra cellular matrix, thrombus formation and atherosclerotic changes like restenosis or angiographic re-narrowing. the reported incidence of restenosis after ptca ranges from 30%-50%. such rates of recurrence have serious economic consequences. bare metal stents (bms), designed to address the limitations of ptca, reduced the angiographic and clinical restenosis rates in de novo lesions compared to ptca alone and decreased the need for cabg. bms substantially reduced the incidence of abrupt artery closure, but restenosis still occurred in about 20%-40% of cases, necessitating repeat procedures. the invention of drug eluting stents (des) significantly improved on the principle of bms by adding an antiproliferative drug (directly immobilised on the stent surface or released from a polymer matrix), which inhibits neointimal hyperplasia. the introduction of des greatly reduced the incidence of restenosis and resulted in a better safety profile as compared to bms with systemic drug administration. these advantages and a lower cost compared to surgical interventions has made des an attractive option to treat coronary artery disease. this observational registry is designed to investigate and collect clinical evidence for the clinical performance and safety of the orsiro drug eluting stent system in an all-comers patient population in daily clinical practice.

Eligibility criteria:
inclusion criteria: * symptomatic coronary artery disease * subject has signed informed consent for data release * subject is geographically stable and willing to participate at all follow-up assessments * subject is ≥ 18 years * elective pci with des exclusion criteria: * subject did not sign informed consent for data release * pregnancy * known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for pci, stainless steel, sirolimus or contrast media * planned surgery within 6 months of pci unless dual antiplatelet therapy will be maintained * currently participating in another study and primary endpoint is not reached yet.

Keywords: international multicenter observational registry orsiro drug eluting stent (des) stenting treatment of coronary artery disease coronary revascularization percutaneous coronary intervention stemi nstemi ischemia angina subgroups acute myocardial infarction diabetes small vessels chronic total occlusion (cto)
central hypothyroidism and cardiovascular risk

Conditions: Hypopituitarism

Summary: retrospective trial of 300 patients with pituitary insufficiency treated in department of medica endocrinology, rigshospitalet, copenhagen university concerning levothyroxine (t4) replacement and cardiovascular risk factors. the hypothesis is that subtle central hypothyroidism is associated with adverse cardiac risk factors, such as body composition and serum lipids, and that improved t4 replacement will eliminate this increased risk, independently of other pituitary hormone replacements.

retrospective trial of 300 patients with pituitary insufficiency treated in department of medical endocrinology, rigshospitalet, copenhagen university concerning levothyroxine (t4) replacement and cardiovascular risk profile. the patient files are recruited among hypopituitary patients treated with growth hormone from the period 1993 to 2008. the trial is a retrospective assessment of data already collected for routine purposes and thus an audit of daily clinical practice. all information on the patients is obtained from the paper and electronic files existing in the department and no new measurements are foreseen.

Eligibility criteria:
inclusion criteria: * all patients with pituitary hypopituitarism exclusion criteria: * unavailability of data

Keywords: central hypothyroidism hypopituitarism levothyroxine replacement lipids body composition
ensuring precision-medicine delivery for veterans with lung cancer

Conditions: Lung Cancer

Summary: the goal of this study is to learn if using a lay va volunteer, who will assist patients with education regarding precision medicine, can improve care quality and outcomes for veteran patients with lung cancer.

participants in the intervention group will receive 1:1 communication with a lay va volunteer in addition to their usual clinical care. the lay va volunteer will provide patients with education about precision medicine and support in their care. researchers will compare a control group who will receive their usual oncology care as provided by clinical teams at the va. there will be no change in their care. all participants will be asked to complete a survey at the time of enrollment in the study, and also at 1 month. this survey will measure patient participation in their cancer care, satisfaction with healthcare decisions, and overall questions about knowledge of precision medicine.

Eligibility criteria:
inclusion criteria: * all patients 18 years old that have been newly diagnosed with any stage of lung cancer. * patients must have the ability to understand and willingness to provide verbal consent. * participants must speak english. exclusion criteria: * inability to consent to the study, severe mental illness (e.g. schizophrenia) or institutionalization. * patients who anticipate moving care outside the veterans affairs palo alto health care system within 6 months.

Keywords: precision medicine lung diseases lay health worker veteran health
temporomandibular disorders and balance performance

Conditions: University Students

Summary: this study aims to investigate the relationship of the temporomandibular joint with head posture, pressure pain threshold, and body balance.

this cross-sectional study was conducted on university students aged 18-30 between april 2024 and december 2024. in the evaluation of the students, the fonseca anamnestic questionnaire was used for temporomandibular joint dysfunction, the research diagnostic criteria for temporomandibular disorders examination form was used for maximum pain-free mouth opening, presence of sound in temporomandibular joint movements, and palpation parameters of the temporomandibular joint and surrounding muscles. an algometer device was used for pressure pain threshold measurement, a goniometer for head-neck posture, emg for measuring the activation of the masseter muscle, and the korebalance premier-19 device for static and dynamic body balance measurement.

Eligibility criteria:
inclusion criteria: * must be a student at bandırma onyedi eylül university * must be willing to participate in the study * aged between 18-30 exclusion criteria: * individuals who have undergone masseter botox treatment * individuals diagnosed with temporomandibular joint disorders and/or bruxism * individuals with musculoskeletal problems showing evidence of specific pathological conditions, such as fractures or rheumatoid diseases related to the lower extremities, spine, and/or temporomandibular joint * individuals who have undergone any surgery related to the lower extremities, spine, and/or temporomandibular joint * individuals who have received physical therapy related to the lower extremities, spine, and/or temporomandibular joint within the last six months * individuals diagnosed with psychiatric disorders

Keywords: head posture masseter body balance temporomandibular joint